Pulmonary involvement in multisystem inflammatory syndrome in children, a diagnostic conundrum: case series from a tertiary care hospital in eastern India
DOI:
https://doi.org/10.18203/2349-3291.ijcp20221861Keywords:
Pediatric, Pulmonary, MIS-CAbstract
In April 2020, a novel syndrome in children and adolescents, termed multisystem inflammatory syndrome in children (MIS-C), related to SARS-CoV-2 (severe acute respiratory syndrome corona virus 2) infection was first described in the United Kingdom and Italy. In this case series, we analysed 6 patients who had moderate to severe respiratory system manifestations at presentation, closely resembling the acute infection. A retrospective analysis of 6 pediatric patients, diagnosed as MIS-C, presenting with predominant respiratory system manifestations between December 2020 to October 2021 was undertaken. All the 6 patients presented with fever and predominant respiratory symptoms which mainly included difficulty in breathing, while two patients had accompanying chest pain. Gastrointestinal symptoms were found to be the most common accompanying systemic involvement. The inflammatory markers were found to be deranged in all the patients. COVID-19 RT-PCR was negative and serology for COVID-19 IgG was positive in all the patients. All the patients were successfully discharged. All were followed up 1 month after discharge. Residual respiratory morbidity was found in none of them. Our case series highlights the importance of distinguishing active covid-19 infection from MIS-C especially in the setting of overlapping clinical features. Timely diagnosis of MIS-C will also prevent unnecessary antibiotic usage.
References
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet (London, England). 2020;395(10237):1607-8.
Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARSCoV-2 epidemic: an observational cohort study. Lancet (London, England). 2020;395(10239):1771-8.
World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific Brief; 2020.
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and Hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol (Hoboken, N.J.). 2020;72(11):1791-805.
Davies P, Evans C, Kanthimathinathan HK. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020;4:669.
Kaushik A, Gupta S, Sood M. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr Infect Dis J. 2020;39:e340.
Radia T, Williams N, Agrawal P. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatr Respir Rev. 2021;38:51.
Ahmed M, Advani S, Moreira A. Multisystem inflammatory syndrome in children: A systematic review. E Clin Med. 2020;26:100527.
Dufort EM. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4):347-58.
Reiff DD, Mannion ML, Samuy N. Distinguishing active pediatric COVID-19 pneumonia from MIS-C. Pediatr Rheumatol. 2021;19:21.
Feldstein LR, Tenforde MW, Friedman KG. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA. 2021;325:1074.
